EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The Therapeutic Future for Congenital Disorders of Glycosylation

I J J Muffels iD, T Kozicz iD, E O Perlstein iD, E Morava iD

Journal of Inherited Metabolic Disease · 2025-03 · 48 (2)

DOI: 10.1002/jimd.70011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 10.03.2025. Verfasst von I J J Muffels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Congenital Disorders of Glycosylation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Rare Disorders Consortium Disease Network (RDCRN), NINDS NIH HHS, National Institute of Child Health and Human Development (NICHD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The past decade, novel treatment options for congenital disorders of glycosylation (CDG) have advanced rapidly. Innovative therapies, targeting both the root cause, the affected metabolic pathways, and resulting manifestations, have transitioned from the research stage to practical applications. However, with novel therapeutic abilities, novel challenges await, specifically when it concerns the large number of clinical trials that need to be performed in order to treat all 190 genetic defects that cause CDG known to date. The present paper aims to provide an overview of how the CDG field can keep advancing its therapeutic strategies over the coming years with these challenges in mind. We focus on three important pillars that may shape the future of CDG: the use of disease models, clinical trial readiness, and the possibility to make individualized treatments scalable to the entire CDG cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Congenital Disorders of GlycosylationHumansGlycosylationClinical Trials as TopicAnimals

Stichwörter der Autor:innen

CDGbasket trialsclinical trial readinesscongenital disorder of glycosylationdisease modelsglycosylationnovel therapies

Autor:innen und Institutionen

  • Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Anatomy, University of Pecs Medical School, Pecs, Hungary.
  • Perlara PBC, Vancouver, WA, USA.
  • Department of Biophysics, University of Pecs Medical School, Pecs, Hungary.

ORCID-Profile: I J J Muffels, T Kozicz, E O Perlstein, E Morava

Förderung

  • Rare Disorders Consortium Disease Network (RDCRN)
  • NINDS NIH HHS
  • National Institute of Child Health and Human Development (NICHD)
  • National Institute of Neurological Diseases and Stroke (NINDS)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Institute of Neurological Disorders and Stroke
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Rare Diseases Clinical Research Network

Zitieren

APA

Muffels, I. J. J., Kozicz, T., Perlstein, E. O., & Morava, E. (2025). The Therapeutic Future for Congenital Disorders of Glycosylation. Journal of Inherited Metabolic Disease, 48(2). https://doi.org/10.1002/jimd.70011

Vancouver

Muffels IJJ, Kozicz T, Perlstein EO, Morava E. The Therapeutic Future for Congenital Disorders of Glycosylation. Journal of Inherited Metabolic Disease. 2025;48(2). doi:10.1002/jimd.70011

BibTeX
@article{Muffels2025,
  author = {Muffels, I J J and Kozicz, T and Perlstein, E O and Morava, E},
  title = {The Therapeutic Future for Congenital Disorders of Glycosylation},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {2},
  doi = {10.1002/jimd.70011}
}
Kostenlos starten →